HRP20100412T1 - Identifikacija površinskih antigena radi dijagnoze i liječenja tumora - Google Patents

Identifikacija površinskih antigena radi dijagnoze i liječenja tumora Download PDF

Info

Publication number: HRP20100412T1
Authority: HR; Croatia
Prior art keywords: tumor; antigen; nucleic acid; fragment; tumor antigen
Prior art date: 2004-05-11

Application number

HR20100412T

Other languages

English (en)

Croatian (hr)

Inventor

Treci Zlem

Sahin Ugur

Schneider Sandra

Helftenbein Gerd

Schl�ter Volker

Usener Dirk

Thiel Philippe

Koslowski Michael

Original Assignee

Ganymed Pharmaceuticals Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-05-11

Filing date

2005-05-11

Publication date

2010-09-30

2005-05-11 Application filed by Ganymed Pharmaceuticals Ag filed Critical Ganymed Pharmaceuticals Ag

2010-09-30 Publication of HRP20100412T1 publication Critical patent/HRP20100412T1/hr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
Analytical Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Microbiology (AREA)
Oncology (AREA)
Pathology (AREA)
General Engineering & Computer Science (AREA)
Physics & Mathematics (AREA)
Biotechnology (AREA)
Epidemiology (AREA)
Hospice & Palliative Care (AREA)
Mycology (AREA)
Biomedical Technology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Cell Biology (AREA)
Urology & Nephrology (AREA)
Peptides Or Proteins (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

HR20100412T 2004-05-11 2005-05-11 Identifikacija površinskih antigena radi dijagnoze i liječenja tumora HRP20100412T1 (hr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE102004023187A DE102004023187A1 (de)	2004-05-11	2004-05-11	Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
PCT/EP2005/005104 WO2005110338A2 (fr)	2004-05-11	2005-05-11	Identification d'antigenes de surface pour le diagnostic et la therapie de tumeurs

Publications (1)

Publication Number	Publication Date
HRP20100412T1 true HRP20100412T1 (hr)	2010-09-30

Family

ID=35064875

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR20100412T HRP20100412T1 (hr)	2004-05-11	2005-05-11	Identifikacija površinskih antigena radi dijagnoze i liječenja tumora

Country Status (14)

Country	Link
US (5)	US7785801B2 (fr)
EP (18)	EP2258867A3 (fr)
JP (6)	JP2007537197A (fr)
AT (1)	ATE468409T1 (fr)
AU (1)	AU2005244425B2 (fr)
CA (2)	CA2820168C (fr)
DE (2)	DE102004023187A1 (fr)
DK (1)	DK1759013T3 (fr)
ES (1)	ES2346067T3 (fr)
HR (1)	HRP20100412T1 (fr)
PL (1)	PL1759013T3 (fr)
PT (1)	PT1759013E (fr)
SI (1)	SI1759013T1 (fr)
WO (1)	WO2005110338A2 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10347710B4 (de)	2003-10-14	2006-03-30	Johannes-Gutenberg-Universität Mainz	Rekombinante Impfstoffe und deren Verwendung
DE102004023187A1 (de) *	2004-05-11	2005-12-01	Ganymed Pharmaceuticals Ag	Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
DE102005046490A1 (de)	2005-09-28	2007-03-29	Johannes-Gutenberg-Universität Mainz	Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
US8535677B2 (en)	2006-06-06	2013-09-17	Oxford Biotherapeutics, Ltd.	Antibody drug conjugate treatment of colorectal cancer
GB0611116D0 (en) *	2006-06-06	2006-07-19	Oxford Genome Sciences Uk Ltd	Proteins
EP2050466B1 (fr) *	2006-08-14	2015-10-28	Chugai Seiyaku Kabushiki Kaisha	Diagnostic et traitement du cancer à l'aide de l'anticorps anti-desmogleine-3
DE102007034993A1 (de) *	2007-07-26	2009-01-29	Hanna Diehl	Lösliches Cadherin 17 für die Diagnose und Risikostratifizierung von Darmtumor oder Darmkrebs
CA2729133C (fr) *	2008-06-25	2014-12-30	Institut Pasteur Korea	Identification visuelle sur l'ensemble du genome de co-facteurs humains de l'infection par le vih-1
WO2010041349A1 (fr) *	2008-10-10	2010-04-15	独立行政法人放射線医学総合研究所	Marqueur pour estimer le pronostic d'un adénocarcinome du col de l'utérus ou pour estimer le pronostic d'un cancer du col de l'utérus
DK2421898T3 (en)	2009-04-20	2016-05-30	Oxford Biotherapeutics Ltd	Cadherin-17 SPECIFIC ANTIBODIES
SG185027A1 (en) *	2010-05-03	2012-11-29	Genentech Inc	Compositions and methods for the diagnosis and treatment of tumor
US20130259878A1 (en) *	2010-10-20	2013-10-03	Oxford Biotherapeutics Ltd	Antibodies
US9511151B2 (en)	2010-11-12	2016-12-06	Uti Limited Partnership	Compositions and methods for the prevention and treatment of cancer
PL3892295T3 (pl)	2011-05-24	2023-07-24	BioNTech SE	Zindywidualizowane szczepionki przeciwnowotworowe
CN102311242B (zh) *	2011-05-27	2014-10-01	刘长福	一种造纸废液生产的水溶性高分子助磨剂及制造方法
KR101314828B1 (ko) *	2011-09-26	2013-10-04	한국원자력연구원	비소세포성 폐암에서 ｔｍ４ｓｆ４의 발현 또는 활성의 조절을 통한 방사선 저항성 및 암세포의 성장, 전이, 및 침윤능력을 저하시키는 방법
WO2013143555A1 (fr)	2012-03-26	2013-10-03	Biontech Ag	Formulation d'arn pour immunothérapie
US10988516B2 (en)	2012-03-26	2021-04-27	Uti Limited Partnership	Methods and compositions for treating inflammation
US9603948B2 (en)	2012-10-11	2017-03-28	Uti Limited Partnership	Methods and compositions for treating multiple sclerosis and related disorders
EP3417874B1 (fr)	2012-11-28	2024-09-11	BioNTech SE	Vaccins individualisés pour le cancer
WO2014180490A1 (fr)	2013-05-10	2014-11-13	Biontech Ag	Prédiction de l'immunogénicité d'épitopes de lymphocytes t
AU2014343379B2 (en)	2013-11-04	2019-02-14	Uti Limited Partnership	Methods and compositions for sustained immunotherapy
CN113791220A (zh)	2014-09-10	2021-12-14	豪夫迈·罗氏有限公司	免疫原性突变体肽筛选平台
WO2016045732A1 (fr)	2014-09-25	2016-03-31	Biontech Rna Pharmaceuticals Gmbh	Formulations stables de lipides et de liposomes
WO2016128060A1 (fr)	2015-02-12	2016-08-18	Biontech Ag	Prédiction des épitopes de lymphocytes t utiles pour la vaccination
JP6492914B2 (ja)	2015-04-15	2019-04-03	株式会社デンソー	光走査装置
ES2939013T3 (es) *	2015-04-20	2023-04-18	Consejo Superior Investigacion	Agentes que se unen específicamente al motivo RGD de la cadherina 17 humana, la cadherina 5 humana, la cadherina 6 humana y la cadherina 20 humana
EP3291832B1 (fr)	2015-05-06	2025-09-03	UTI Limited Partnership	Compositions de nanoparticules pour thérapie prolongée
US11254744B2 (en)	2015-08-07	2022-02-22	Imaginab, Inc.	Antigen binding constructs to target molecules
WO2017059902A1 (fr)	2015-10-07	2017-04-13	Biontech Rna Pharmaceuticals Gmbh	Séquences utr 3' permettant la stabilisation d'arn
SI3383920T1 (sl)	2015-11-30	2024-06-28	The Regents Of The University Of California	Dostava tumorsko specifičnega koristnega tovora in imunska aktivacija z uporabo humanega protitelesa, ki cilja visoko specifičen površinski antigen tumorskih celic
ES2970865T3 (es)	2015-12-16	2024-05-31	Gritstone Bio Inc	Identificación, fabricación y uso de neoantígenos
US11241455B2 (en)	2016-01-15	2022-02-08	The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone	Methods of treating disease by metabolic control of T-cell differentiation
US11266745B2 (en)	2017-02-08	2022-03-08	Imaginab, Inc.	Extension sequences for diabodies
CN106919801B (zh) *	2017-03-08	2023-07-18	杭州大伽信息科技有限公司	一种免疫组织化学染色辅助分析系统及使用方法
WO2018224166A1 (fr)	2017-06-09	2018-12-13	Biontech Rna Pharmaceuticals Gmbh	Procédés de prédiction de l'utilité de modifications d'acides aminés spécifiques d'une maladie pour l'immunothérapie
EP4576103A3 (fr)	2017-10-10	2025-08-27	Gritstone bio, Inc.	Identification de néoantigènes à l'aide de points chauds
CN111630602A (zh)	2017-11-22	2020-09-04	磨石肿瘤生物技术公司	减少新抗原的接合表位呈递
CA3083748A1 (fr)	2017-11-29	2019-06-06	Uti Limited Partnership	Methodes de traitement d'une maladie auto-immune
WO2019183683A1 (fr) *	2018-03-29	2019-10-03	The University Of Newcastle	Procédés de diagnostic et de pronostic pour des cancers induits par les oestrogènes
WO2020263796A1 (fr) *	2019-06-23	2020-12-30	Guangdong Tcrcure Biopharma Technology Co., Ltd.	Thérapie par cellules car-t anti-alpp
US12421309B2 (en)	2019-12-06	2025-09-23	Korea Atomic Energy Research Institute	Anti-TM4SF4 antibody and uses thereof
CN117597363A (zh) *	2021-06-18	2024-02-23	韩国原子力研究院	抗-tm4sf4人源化抗体及其用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4732847A (en) *	1981-06-09	1988-03-22	University Of Hawaii	Monoclonal antibodies for DNA-RNA hybrid complexes and their uses
US5081227A (en) *	1988-03-04	1992-01-14	La Jolla Cancer Research Foundation	Germ cell alkaline phosphatase
GB9019812D0 (en)	1990-09-11	1990-10-24	Scotgen Ltd	Novel antibodies for treatment and prevention of infection in animals and man
AU3178393A (en)	1991-11-27	1993-06-28	United States Of America, Represented By The Secretary, Department Of Health And Human Services, The	Nucleotide and amino acid sequence of pemphigus vulgaris antigen and methods of use
US5677139A (en)	1995-04-21	1997-10-14	President And Fellows Of Harvard College	In vitro differentiation of CD34+ progenitor cells into T lymphocytes
UA56132C2 (uk)	1995-04-25	2003-05-15	Смітклайн Бічем Байолоджікалс С.А.	Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
CA2243235C (fr)	1996-01-17	2010-08-10	Imperial College Innovations Limited	Immunotherapie utilisant des lymphocytes t cytotoxiques (ctl)
JP2003530816A (ja)	1998-09-28	2003-10-21	カイロンコーポレイション	ヒト遺伝子および遺伝子発現産物
EP1252300B1 (fr) *	2000-02-03	2011-01-19	Dendreon Corporation	Molecules d'acides nucleiques codant pour des proteases a serine transmembranaires, proteines codees et procedes associes
KR100374423B1 (ko) *	2000-04-25	2003-03-28	주식회사 아이씨엔지	다수의 ｍａｇｅ 아형 또는 ｇａｇｅ 아형을 인식하는암진단용 프라이머
CA2411601A1 (fr) *	2000-06-05	2001-12-13	Avalon Pharmaceuticals	Determination de gene du cancer et recherche therapeutique utilisant des ensembles de genes signature
ES2284678T3 (es) *	2000-08-15	2007-11-16	Immunex Corporation	Polipeptidos de claudinas.
US6697557B2 (en) *	2000-10-04	2004-02-24	University Of South Florida	Two-dimensional optical filter and associated methods
DE10057894A1 (de) *	2000-11-22	2002-06-06	Adnagen Gmbh	Diagnose-Kit, DNS-Chip sowie Verfahren zur Diagnostik oder Behandlungskontrolle bei Hodenkrebs
AU2002309583A1 (en)	2001-04-18	2002-11-05	Protein Desing Labs, Inc.	Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
US20050037445A1 (en) *	2001-06-25	2005-02-17	Poulsen Hans Skovgaard	Oncology drug innovation
US20040076955A1 (en) *	2001-07-03	2004-04-22	Eos Biotechnology, Inc.	Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
WO2003018621A2 (fr) *	2001-08-23	2003-03-06	Oxford Biomedica (Uk) Limited	Genes
JP2003088388A (ja) *	2001-09-14	2003-03-25	Herikkusu Kenkyusho:Kk	新規な全長ｃＤＮＡ
EP1293569A3 (fr) *	2001-09-14	2004-03-31	Research Association for Biotechnology	Clones d'ADNc complets
DE10211088A1 (de)	2002-03-13	2003-09-25	Ugur Sahin	Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE10254601A1 (de) *	2002-11-22	2004-06-03	Ganymed Pharmaceuticals Ag	Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
CA2522184A1 (fr) *	2003-04-17	2004-11-04	The Trustees Of Columbia University In The City Of New York	Desmogleine 4, nouveau gene de la croissance des cheveux
WO2004106511A1 (fr) *	2003-05-30	2004-12-09	Nippon Shinyaku Co., Ltd.	Arn oligobicatenaire inhibant l'expression de bcl-2 et composition medicinale contenant cet arn
DE102004023187A1 (de)	2004-05-11	2005-12-01	Ganymed Pharmaceuticals Ag	Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie

2004
- 2004-05-11 DE DE102004023187A patent/DE102004023187A1/de not_active Withdrawn
2005
- 2005-05-11 EP EP10010161A patent/EP2258867A3/fr not_active Withdrawn
- 2005-05-11 HR HR20100412T patent/HRP20100412T1/hr unknown
- 2005-05-11 US US11/596,106 patent/US7785801B2/en not_active Expired - Lifetime
- 2005-05-11 JP JP2007512091A patent/JP2007537197A/ja active Pending
- 2005-05-11 EP EP10010164A patent/EP2287337A3/fr not_active Withdrawn
- 2005-05-11 EP EP10010156A patent/EP2348135A3/fr not_active Withdrawn
- 2005-05-11 PT PT05747772T patent/PT1759013E/pt unknown
- 2005-05-11 EP EP10005074A patent/EP2239340A3/fr not_active Withdrawn
- 2005-05-11 CA CA2820168A patent/CA2820168C/fr not_active Expired - Lifetime
- 2005-05-11 EP EP10010168A patent/EP2267158A3/fr not_active Withdrawn
- 2005-05-11 PL PL05747772T patent/PL1759013T3/pl unknown
- 2005-05-11 EP EP10010160A patent/EP2290104A3/fr not_active Withdrawn
- 2005-05-11 EP EP10010157A patent/EP2275570A3/fr not_active Withdrawn
- 2005-05-11 ES ES05747772T patent/ES2346067T3/es not_active Expired - Lifetime
- 2005-05-11 EP EP10010166A patent/EP2267157A3/fr not_active Withdrawn
- 2005-05-11 SI SI200531066T patent/SI1759013T1/sl unknown
- 2005-05-11 AT AT05747772T patent/ATE468409T1/de active
- 2005-05-11 EP EP10010162A patent/EP2258868A3/fr not_active Withdrawn
- 2005-05-11 WO PCT/EP2005/005104 patent/WO2005110338A2/fr not_active Ceased
- 2005-05-11 AU AU2005244425A patent/AU2005244425B2/en not_active Ceased
- 2005-05-11 EP EP10010167A patent/EP2270209A3/fr not_active Withdrawn
- 2005-05-11 DE DE502005009602T patent/DE502005009602D1/de not_active Expired - Lifetime
- 2005-05-11 EP EP05747772A patent/EP1759013B1/fr not_active Expired - Lifetime
- 2005-05-11 CA CA002563671A patent/CA2563671A1/fr not_active Abandoned
- 2005-05-11 EP EP10010165A patent/EP2267156A3/fr not_active Withdrawn
- 2005-05-11 EP EP10010163A patent/EP2258869A3/fr not_active Withdrawn
- 2005-05-11 EP EP10010158A patent/EP2290103A3/fr not_active Withdrawn
- 2005-05-11 DK DK05747772.1T patent/DK1759013T3/da active
- 2005-05-11 EP EP18157525.9A patent/EP3382036A1/fr not_active Withdrawn
- 2005-05-11 EP EP10010155.9A patent/EP2280082B1/fr not_active Expired - Lifetime
- 2005-05-11 EP EP10010159A patent/EP2275571A3/fr not_active Withdrawn
- 2005-05-11 EP EP10010640A patent/EP2275572A3/fr not_active Withdrawn
2010
- 2010-08-06 US US12/851,980 patent/US9255131B2/en not_active Expired - Fee Related
2011
- 2011-10-18 JP JP2011229287A patent/JP5732369B2/ja not_active Expired - Fee Related
2012
- 2012-10-16 JP JP2012228762A patent/JP5796003B2/ja not_active Expired - Lifetime
2013
- 2013-09-25 US US14/036,969 patent/US9533043B2/en not_active Expired - Lifetime
2014
- 2014-11-28 JP JP2014240820A patent/JP2015083576A/ja active Pending
2016
- 2016-01-28 US US15/009,061 patent/US20160193335A1/en not_active Abandoned
- 2016-04-25 JP JP2016086914A patent/JP6434444B2/ja not_active Expired - Lifetime
2017
- 2017-08-11 US US15/675,148 patent/US10724103B2/en not_active Expired - Lifetime
2018
- 2018-03-09 JP JP2018042560A patent/JP2018104464A/ja active Pending

Also Published As

Publication number	Publication date
EP2290104A3 (fr)	2011-06-22
JP2015083576A (ja)	2015-04-30
EP2348135A3 (fr)	2011-10-19
EP2270209A3 (fr)	2011-04-20
EP2267158A3 (fr)	2011-04-06
EP2290103A3 (fr)	2011-06-22
EP2290103A2 (fr)	2011-03-02
EP1759013B1 (fr)	2010-05-19
JP2012077085A (ja)	2012-04-19
EP2258867A2 (fr)	2010-12-08
EP2280082A3 (fr)	2011-05-18
EP2239340A2 (fr)	2010-10-13
JP5732369B2 (ja)	2015-06-10
CA2563671A1 (fr)	2005-11-24
EP2290104A2 (fr)	2011-03-02
EP2267156A3 (fr)	2011-04-20
PT1759013E (pt)	2010-08-17
AU2005244425B2 (en)	2011-10-13
EP2275570A2 (fr)	2011-01-19
US10724103B2 (en)	2020-07-28
US9255131B2 (en)	2016-02-09
EP2275571A2 (fr)	2011-01-19
JP2013032381A (ja)	2013-02-14
EP2280082A2 (fr)	2011-02-02
JP2016179986A (ja)	2016-10-13
US7785801B2 (en)	2010-08-31
EP1759013A2 (fr)	2007-03-07
EP2267158A2 (fr)	2010-12-29
JP5796003B2 (ja)	2015-10-21
EP2287337A3 (fr)	2011-04-20
EP2258869A3 (fr)	2011-04-06
EP2267156A2 (fr)	2010-12-29
AU2005244425A1 (en)	2005-11-24
EP2258869A2 (fr)	2010-12-08
EP2258867A3 (fr)	2011-04-06
EP2275571A3 (fr)	2012-11-21
DE502005009602D1 (de)	2010-07-01
EP2270209A2 (fr)	2011-01-05
JP2018104464A (ja)	2018-07-05
ES2346067T3 (es)	2010-10-08
EP2287337A2 (fr)	2011-02-23
EP2275570A3 (fr)	2011-06-22
US20140120085A1 (en)	2014-05-01
US20110014628A1 (en)	2011-01-20
DK1759013T3 (da)	2010-08-30
DE102004023187A1 (de)	2005-12-01
EP2267157A3 (fr)	2011-05-11
CA2820168A1 (fr)	2005-11-24
JP2007537197A (ja)	2007-12-20
EP2258868A3 (fr)	2011-04-06
SI1759013T1 (sl)	2010-09-30
JP6434444B2 (ja)	2018-12-05
PL1759013T3 (pl)	2010-10-29
CA2820168C (fr)	2019-08-20
US9533043B2 (en)	2017-01-03
ATE468409T1 (de)	2010-06-15
WO2005110338A3 (fr)	2006-06-29
EP2275572A3 (fr)	2011-05-11
EP2267157A2 (fr)	2010-12-29
EP2275572A2 (fr)	2011-01-19
WO2005110338A2 (fr)	2005-11-24
US20160193335A1 (en)	2016-07-07
EP2239340A3 (fr)	2010-11-17
US20180169236A1 (en)	2018-06-21
EP2348135A2 (fr)	2011-07-27
EP2280082B1 (fr)	2016-08-10
US20080193454A1 (en)	2008-08-14
EP2258868A2 (fr)	2010-12-08
EP3382036A1 (fr)	2018-10-03

Publication	Publication Date	Title
HRP20100412T1 (hr)	2010-09-30	Identifikacija površinskih antigena radi dijagnoze i liječenja tumora
EP2624866B1 (fr)	2022-07-06	Anticorps spécifiques à une tumeur et utilisations de ceux-ci
RU2013113439A (ru)	2014-10-10	Идентификация опухолеассоциированных антигенов для диагностики и терапии
ES2769831T3 (es)	2020-06-29	Método para detectar cáncer
ES2718348T3 (es)	2019-07-01	Método para detectar cáncer
KR102047502B1 (ko)	2019-11-22	포타슘 채널 단백질을 이용한 암 진단용 조성물
ES2398328B1 (es)	2014-02-05	Métodos y productos para el diagnóstico in vitro, pronóstico in vitro y desarrollo de fármacos contra carcinomas invasivos.
Lee et al.	2012	CA215 and GnRH receptor as targets for cancer therapy
BR112020003694B1 (pt)	2024-03-12	Anticorpos úteis no diagnóstico do câncer
CN101416058A (zh)	2009-04-22	Wnt蛋白及癌症的检测与治疗
CN117430700A (zh)	2024-01-23	一种抗波形蛋白的抗体或其抗原结合片段、试剂盒及应用
RU2020127079A (ru)	2022-02-17	Применение белка tas1r3 в качестве маркера для терапевтических, диагностических и/или прогностических целей для опухолей, которые экспрессируют указанный белок
AU2006279633A1 (en)	2007-02-22	Human monoclonal antibodies that specifically bind IGF-II
ES2271892T3 (es)	2007-04-16	Uso de la proteina masp como marcador para el cancer colorrectal.
JP2008535855A5 (fr)	2009-03-26
JPWO2012029990A1 (ja)	2013-10-31	大腸がんマーカーに対する抗体
ES2285469T3 (es)	2007-11-16	Utilizacion de la proteina celular transportadora de acido retinoico de tipo ii (crabp ii) como marcador del cancer de mama.
US7824681B2 (en)	2010-11-02	Human monoclonal antibodies that specifically bind IGF-II
KR102216386B1 (ko)	2021-02-17	암의 진단용 조성물
JP2006104212A5 (fr)	2008-09-18
JP2007077155A5 (fr)	2008-09-18
ES2315673T3 (es)	2009-04-01	Uso de la subunidad de 3 de proteina activadora de proteasoma (pse3) como marcador de cancer colorrectal.
JP2012525121A5 (fr)	2013-05-30
US20110171216A1 (en)	2011-07-14	Monoclonal antibodies specific for pancreatic neoplasia cells
JP2023133869A (ja)	2023-09-27	卵巣がん患者の予後予測用バイオマーカー